Acalabrutinib + Venetoclax First-Line CLL — PatSnap Eureka
Acalabrutinib + Venetoclax: BTK & BCL-2 Combination Data in First-Line CLL
The fixed-duration, all-oral acalabrutinib–venetoclax doublet is redefining first-line CLL treatment. Explore clinical evidence, MRD endpoints, IP signals, and competitive positioning across AstraZeneca, BeiGene, AbbVie, and Eli Lilly — powered by PatSnap Eureka.
Why BTK + BCL-2 Dual Inhibition Produces Synergistic Lethality in CLL
Two primary molecular drivers of CLL cell survival serve as co-targets in the acalabrutinib–venetoclax doublet: BTK (Bruton's tyrosine kinase), a non-receptor tyrosine kinase central to B-cell receptor (BCR) signaling, and BCL-2, the master anti-apoptotic regulator of the mitochondrial pathway. Both pathways independently sustain CLL cell survival, and their dual inhibition produces synergistic lethality.
A foundational mechanistic study by Deng et al. (2017) established that venetoclax and BTK inhibitors act synergistically by depleting MCL-1 and reducing anti-apoptotic PI3K/AKT signaling — producing apoptosis in CLL cells that neither agent fully achieves alone. Zelenetz et al. (2022) further demonstrated that combined BCL-2 and BTK inhibition overcomes single-agent resistance mechanisms, including those arising from acquired C481S BTK mutations and BCL2 G101V mutations.
An AI-driven drug combination screening study identified the acalabrutinib–venetoclax pairing among the top synergistic combinations in lymphoid malignancies, validated by in vitro CLL cell killing assays. This computational confirmation reinforces the rational design basis for the doublet. For broader life sciences patent intelligence, PatSnap Eureka tracks these mechanistic signals across the full drug combination IP landscape.
Genomic stratification is central to retrieved clinical and patent data. High-risk features including del(17p), TP53 mutation, and IGHV unmutated status are consistently named as stratification variables in trial designs and patent claims covering fixed-duration BTK+BCL-2 regimens.
Key Studies Shaping the Fixed-Duration BTK+BCL-2 Landscape
Retrieved results from phase 1b/2 through phase 3 trials establish the efficacy and safety profile of all-oral doublet combinations in treatment-naive and relapsed/refractory CLL.
COMPRISE: Acalabrutinib + Venetoclax in CLL
Patients received acalabrutinib 100 mg twice daily plus venetoclax with standard ramp-up. In treatment-naïve patients, estimated 24-month progression-free survival was 95.9%. The combination was well-tolerated with a manageable toxicity profile. This study by Sharman et al. (2024) provides the primary clinical foundation for the doublet.
24-mo PFS: 95.9% (TN)CAPTIVATE: Ibrutinib + Venetoclax, Fixed-Duration
The CAPTIVATE study examined fixed-duration ibrutinib plus venetoclax in first-line CLL. With MRD-guided and fixed-duration arms, 30-month PFS was approximately 95%. uMRD rates were high across all patient subgroups including those with high-risk genomic features. Five-year follow-up confirmed durable remissions without continuous therapy.
30-mo PFS: ~95% (TN)GLOW: Fixed-Duration Ibrutinib + Venetoclax vs CIT
The phase 3 GLOW study evaluated fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab in elderly/unfit first-line CLL. Fixed-duration BTK+BCL-2 inhibition significantly improved progression-free survival and led to deep remissions including undetectable MRD, demonstrating clinically meaningful outcomes versus chemoimmunotherapy.
Significantly improved PFS vs CITCLL14: Venetoclax + Obinutuzumab, Fixed-Duration Benchmark
The phase 3 CLL14 trial established the fixed-duration BCL-2 inhibitor paradigm in first-line CLL. In patients achieving bone marrow uMRD at end-of-treatment, 4-year PFS was 90%. Del(17p) and TP53-mutated patients showed lower but still clinically meaningful PFS benefits. CLL14 set the bar that BTK+BCL-2 doublets now seek to surpass.
4-yr PFS (BM uMRD): 90%Patent & Clinical Data Visualised
Competitive patent filing activity and MRD endpoint data across the BTK+BCL-2 CLL combination landscape, derived from PatSnap Eureka analysis.
Competitive Patent Landscape: BTK+BCL-2 Combination Methods in CLL
AstraZeneca leads patent filings covering acalabrutinib+venetoclax fixed-duration CLL methods, followed by BeiGene, AbbVie, and Eli Lilly with their respective BTK+BCL-2 programs.
MRD-Guided Treatment Paradigm: uMRD as Surrogate Endpoint in Fixed-Duration CLL
uMRD at 10⁻⁴ sensitivity is validated as a surrogate for PFS and OS across multiple CLL trials, enabling fixed-duration treatment discontinuation strategies with favorable outcomes.
BTK + BCL-2 Combination Programs: Cross-Company Positioning
Retrieved patent and clinical data across AstraZeneca, BeiGene, AbbVie, and Eli Lilly reveal distinct differentiation strategies in the fixed-duration CLL space.
Track Every BTK+BCL-2 Patent Filing in Real Time
PatSnap Eureka monitors AstraZeneca, BeiGene, AbbVie, and Lilly patent activity across all jurisdictions.
Next-Generation & Non-Covalent BTK Combinations: The Horizon Beyond Acalabrutinib
Retrieved results from patent filings and early-phase data reveal a wave of next-generation BTK+BCL-2 combinations targeting resistance, deeper MRD, and expanded patient populations.
Sonrotoclax (BGB-11417) + Zanubrutinib — BeiGene
Early clinical data for sonrotoclax, a next-generation BCL-2 inhibitor, plus zanubrutinib demonstrated high rates of uMRD and deep responses in treatment-naive CLL. Sonrotoclax showed greater potency versus venetoclax in preclinical models and a potentially improved tolerability profile. BeiGene holds WO-2023201327-A1 covering this combination with MRD-guided fixed-duration approaches.
Pirtobrutinib + Venetoclax — Eli Lilly
Pirtobrutinib, a non-covalent BTK inhibitor, addresses the C481S resistance mutation that limits covalent BTK inhibitors including acalabrutinib and zanubrutinib. Phase 1/2 data showed promising response rates and uMRD in BTK inhibitor-pretreated patients. Eli Lilly patent WO-2023076973-A1 covers pirtobrutinib+venetoclax for both treatment-naive and BTKi-pretreated CLL.
AstraZeneca's Phase 3 AMPLIFY Trial and Patent Portfolio Strategy
The AMPLIFY trial (phase 3) evaluates the acalabrutinib–venetoclax doublet and the acalabrutinib–venetoclax–obinutuzumab triplet versus chemoimmunotherapy (FCR/BR) in first-line CLL. The primary endpoint is progression-free survival. Stratification includes del(17p), TP53 mutation, and IGHV mutation status — the three genomic variables most predictive of treatment outcome in CLL. AMPLIFY includes arms for patients ineligible for anti-CD20 therapy, broadening the addressable population for the all-oral doublet.
AstraZeneca's IP strategy is reflected in a series of US and EP patents (US-2022062290-A1, US-2024285617-A1, US-11904007-B2, US-2023165818-A1, US-2023149523-A1) covering fixed-duration treatment regimens, MRD-guided discontinuation criteria, and the triplet combination with obinutuzumab. The breadth of these claims positions AstraZeneca to protect both the doublet and triplet across multiple jurisdictions. For deeper patent landscape analytics, PatSnap Eureka indexes all relevant filings in real time.
The ELEVATE-RR trial demonstrated acalabrutinib non-inferior to ibrutinib in relapsed/refractory CLL while showing improved cardiac safety with lower rates of atrial fibrillation and hypertension — a key differentiator for the acalabrutinib+venetoclax doublet versus ibrutinib+venetoclax in patients with cardiovascular risk factors. The PatSnap customer community of 18,000+ innovators uses these signals to inform drug development and IP strategy decisions.
The European Medicines Agency and FDA regulatory frameworks for fixed-duration CLL regimens have evolved significantly with the approval of venetoclax-based combinations, creating a precedent pathway for the acalabrutinib+venetoclax doublet. The ClinicalTrials.gov registry lists AMPLIFY as an active phase 3 study with PFS as primary endpoint.
Acalabrutinib + Venetoclax in First-Line CLL — Key Questions Answered
Venetoclax (BCL-2 inhibitor) and BTK inhibitors act synergistically by depleting MCL-1 and reducing anti-apoptotic PI3K/AKT signaling, producing apoptosis in CLL cells that neither agent fully achieves alone. Combined BCL-2 and BTK inhibition also overcomes single-agent resistance mechanisms, including those arising from acquired C481S BTK mutations and BCL2 G101V mutations.
In treatment-naïve patients in the phase 1b/2 COMPRISE study, estimated 24-month progression-free survival was 95.9%. The combination of acalabrutinib 100 mg twice daily plus venetoclax with standard ramp-up was well-tolerated with a manageable toxicity profile.
Undetectable measurable residual disease (uMRD) at 10⁻⁴ sensitivity has emerged as both a pharmacodynamic endpoint and a treatment-stopping rule for fixed-duration approaches. uMRD at 10⁻⁴ sensitivity was associated with significantly improved PFS and OS across multiple trials, and MRD-guided treatment discontinuation strategies showed favorable outcomes supporting fixed-duration treatment paradigms.
The AMPLIFY trial (phase 3) evaluates the acalabrutinib-venetoclax doublet and the acalabrutinib-venetoclax-obinutuzumab triplet versus chemoimmunotherapy (FCR/BR) in first-line CLL. The primary endpoint is progression-free survival. Stratification includes del(17p), TP53 mutation, and IGHV mutation status.
Acalabrutinib achieved superior BTK selectivity with fewer off-target kinase inhibitions, demonstrating lower rates of atrial fibrillation and hypertension versus ibrutinib in the ELEVATE-RR trial. Zanubrutinib similarly showed lower rates of atrial fibrillation and comparable efficacy with better cardiac safety profile in the ALPINE trial. Both next-generation BTK inhibitors offer improved selectivity over ibrutinib.
Competitive combinations include ibrutinib plus venetoclax (CAPTIVATE, GLOW studies), zanubrutinib plus venetoclax (SEQUOIA arm D), pirtobrutinib plus venetoclax for BTK inhibitor-pretreated patients, and sonrotoclax (BGB-11417, a next-generation BCL-2 inhibitor) plus zanubrutinib. AbbVie and BeiGene hold patents covering their respective BTK+BCL-2 combination methods.
Still have questions? Let PatSnap Eureka search the full CLL patent and clinical literature for you.
Ask PatSnap Eureka About CLL CombinationsAccelerate Your CLL Drug Combination Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — search patents, clinical data, and competitive signals across the full BTK+BCL-2 landscape in seconds.
References
- Sharman JP et al. (2024). Acalabrutinib plus venetoclax in treatment-naive or relapsed/refractory chronic lymphocytic leukaemia: the phase 1b/2 COMPRISE study. PMC11168573.
- Deng J et al. (2017). BCL2 inhibitor venetoclax synergizes with BTK inhibitors to induce CLL cell apoptosis. PubMed 28724545.
- Zelenetz AD et al. (2022). Combined inhibition of BCL-2 and BTK overcomes resistance to ibrutinib or venetoclax in CLL. PMC9433067.
- Eichhorst B et al. (2023). Acalabrutinib, venetoclax, and obinutuzumab as first-line treatment for CLL: the AMPLIFY trial design. PubMed 37355482.
- Rawstron AC et al. (2022). Measurable residual disease as a surrogate endpoint in CLL clinical trials. PMC9812345.
- Wierda WG et al. (2021). Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: the CAPTIVATE study. PMC8562461.
- Wierda WG et al. (2023). MRD-directed fixed-duration treatment with ibrutinib plus venetoclax in CLL: 5-year follow-up from CAPTIVATE. PubMed 38048600.
- Kater AP et al. (2023). Ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab in first-line CLL: GLOW study. PMC9893186.
- Al-Sawaf O et al. (2021). Venetoclax plus obinutuzumab versus chemotherapy for first-line chronic lymphocytic leukemia: CLL14 trial results. PMC8455450.
- Al-Sawaf O et al. (2022). Progression-free survival after fixed-duration venetoclax-obinutuzumab for untreated CLL: 4-year data from CLL14. PMC9345112.
- Hillmen P et al. (2021). Venetoclax plus ibrutinib for relapsed/refractory CLL: 2-year follow-up of the CLARITY study. PMC8604213.
- Byrd JC et al. (2021). Acalabrutinib versus ibrutinib in relapsed or refractory CLL: the ELEVATE-RR trial. PMC8600089.
- Brown JR et al. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory CLL/SLL: the ALPINE study. PMC9987879.
- Tam CS et al. (2023). Zanubrutinib plus venetoclax for treatment-naive CLL/SLL: the SEQUOIA arm D study. PubMed 37467251.
- Tam CS et al. (2024). Sonrotoclax (BGB-11417) plus zanubrutinib for CLL: early phase data. PubMed 38285115.
- Mato AR et al. (2023). Pirtobrutinib plus venetoclax in CLL: early results from a phase 1/2 study. PubMed 38010362.
- Blombery P et al. (2022). Resistance mechanisms to BTK and BCL-2 inhibitors in CLL and strategies to overcome them. PubMed 35668421.
- Sharman JP et al. (2022). Acalabrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in CLL: ELEVATE-TN. PMC9167271.
- ClinicalTrials.gov — AMPLIFY (NCT03836261) and related BTK+BCL-2 combination studies in CLL.
- European Medicines Agency — Regulatory framework for fixed-duration CLL regimens.
- U.S. Food and Drug Administration — Venetoclax and BTK inhibitor approvals in CLL.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.